{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:57:27Z","timestamp":1769090247401,"version":"3.49.0"},"reference-count":20,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,6,8]]},"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>A 33-year-old male presenting with subacute abdominal pain was found to have hyperbilirubinaemia, hypokalaemia and hyponatraemia. This was in the setting of transitioning between deferasirox iron chelator formulations, from dispersible tablets to film-coated tablets for ongoing treatment of chronic iron overload secondary to transfusion requirement for beta-thalassemia major. A liver biopsy demonstrated acute cholestasis with patchy confluent hepatocellular necrosis and mild to moderate microvesicular steatosis. Based on the histological, biochemical and clinical findings, the diagnosis of hepatotoxicity and Fanconi-like syndrome was made. The patient improved clinically and biochemically with cessation of the deferasirox film-coated tablets and supportive management. To our knowledge, this is the first case report of hepatotoxicity and Fanconi-like syndrome occurring due to deferasirox film-coated tablets with previous tolerance of dispersible deferasirox tablets. It is important to raise clinical awareness of this potentially severe complication.<\/jats:p>","DOI":"10.1136\/bcr-2020-234542","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T01:45:18Z","timestamp":1594345518000},"page":"e234542","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Deferasirox-induced liver injury and Fanconi syndrome in a beta-thalassemia major male"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1534-1919","authenticated-orcid":false,"given":"Jacqueline","family":"Fraser","sequence":"first","affiliation":[{"name":"Gastroenterology and Hepatology Department, Austin Health, Heidelberg, Victoria, Australia"},{"name":"Gastroenterology and Hepatology Department, Northern Health, Epping, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rowena","family":"Brook","sequence":"additional","affiliation":[{"name":"Haematology Department, Northern Health, Epping, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"He","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Department, Austin Health, Heidelberg, Victoria, Australia"},{"name":"Gastroenterology and Hepatology Department, Northern Health, Epping, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Lewis","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Department, Northern Health, Epping, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"2025082722574787000_13.7.e234542.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3430"},{"key":"2025082722574787000_13.7.e234542.2","unstructured":"U.S. National Library of Medicine . Deferasirox, 2019. Available: https:\/\/livertox.nlm.nih.gov\/Deferasirox.htm"},{"key":"2025082722574787000_13.7.e234542.3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ajh.24668","article-title":"New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: results of the randomized, phase II eclipse study","volume":"92","author":"Taher","year":"2017","journal-title":"Am J Hematol"},{"key":"2025082722574787000_13.7.e234542.4","unstructured":"Novartis Pharmaceuticals . Jadenu (deferasirox) tablets and Jadenu Sprinkle (deferasirox) granules: US prescribing information, 2018. Available: www.pharma.us.novartis.com\/product\/pi\/pdf\/jadenu.pdf"},{"key":"2025082722574787000_13.7.e234542.5","unstructured":"Exjade (deferasirox) [prescribing information]. Stein, Switz Novartis Pharm Corporation, 2019. Available: https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/exjade.pdf"},{"key":"2025082722574787000_13.7.e234542.6","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/ajh.23569","article-title":"Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea","volume":"88","author":"Vichinsky","year":"2013","journal-title":"Am J Hematol"},{"key":"2025082722574787000_13.7.e234542.7","first-page":"101","article-title":"Deferasirox: appraisal of safety and efficacy in long-term therapy","volume":"4","author":"Chaudhary","year":"2013","journal-title":"J Blood Med"},{"key":"2025082722574787000_13.7.e234542.8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4081\/hr.2015.5987","article-title":"Acute liver failure in a pediatric patient with congenital dyserythropoietic anemia type I treated with deferasirox","volume":"7","author":"Ling","year":"2015","journal-title":"Hematol Rep"},{"key":"2025082722574787000_13.7.e234542.9","first-page":"551","article-title":"Deferasirox induced liver injury in haemochromatosis","volume":"20","author":"Aslam","year":"2010","journal-title":"J Coll Physicians Surg Pak"},{"key":"2025082722574787000_13.7.e234542.10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MPH.0000000000000654","article-title":"Fulminant liver failure in a child with \u03b2-thalassemia on deferasirox","volume":"39","author":"Ramaswami","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"2025082722574787000_13.7.e234542.11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/15563650.2018.1523425","article-title":"Acute hyperammonemia in children under deferasirox treatment: cutting the Gordian knot","volume":"57","author":"Martinelli","year":"2019","journal-title":"Clin Toxicol"},{"key":"2025082722574787000_13.7.e234542.12","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181ec0c38"},{"key":"2025082722574787000_13.7.e234542.13","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq224"},{"key":"2025082722574787000_13.7.e234542.14","first-page":"177","article-title":"A case report of deferasirox-induced kidney injury and Fanconi syndrome","volume":"112","author":"Murphy","year":"2013","journal-title":"WMJ"},{"key":"2025082722574787000_13.7.e234542.15","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22711"},{"key":"2025082722574787000_13.7.e234542.16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/MPH.0000000000000786","article-title":"Acute liver failure during deferasirox chelation: a toxicity worth considering","volume":"39","author":"Menaker","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"2025082722574787000_13.7.e234542.17","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-113998","article-title":"Jadenu substituting Exjade in beta thalassemia major (BTM) patients with iron overload: effect on serum ferritin concentration, liver iron content and biochemical profiles","volume":"132","author":"Yassin","year":"2018","journal-title":"Blood"},{"key":"2025082722574787000_13.7.e234542.18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ejh.13111","article-title":"Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes","volume":"101","author":"Kattamis","year":"2018","journal-title":"Eur J Haematol"},{"key":"2025082722574787000_13.7.e234542.19","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-114601","article-title":"Iron chelation therapy of thalassemia patients is still a challenge. single centre experience from United Arab Emirates","volume":"132","author":"Osman","year":"2018","journal-title":"Blood"},{"key":"2025082722574787000_13.7.e234542.20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4748.4748","article-title":"Iron chelation therapy: a review of the literature on the issues and importance of adherence to treatment in iron overload","volume":"126","author":"Huang","year":"2015","journal-title":"Blood"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-234542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:57:53Z","timestamp":1756360673000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-234542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7,9]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/bcr-2020-234542"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-234542","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}